

VOLUMEN XLIX

NUMERUS suppl 1

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2021

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Petar Suton – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Željko Herceg, Ljiljana Mayer, Aleksandar Milenović, Marija Pastorčić-Grgić, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Sanda Šitić, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), G. Fisher (Stanford, USA), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), D. Marčinko (Zagreb, Croatia), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), R. Pirker (Wien, Austria), B.I. Šikić (Stanford, USA), I. Tomaš (Osijek, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA), M. Zovak (Zagreb, Croatia).

Indexed in SCOPUS and EMBASE/Excerpta Medica

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



HRVATSKO ONKOLOŠKO DRUŠTVO

14 HRVATSKI ONKOLOŠKI KONGRES 14th CROATIAN ONCOLOGY CONGRESS

22. - 25. 04. 2021
VIRTUAL CONGRESS

Supplement editors:
Eduard Vrdoljak and Marijana Jazvić

Zagreb, Croatia
April, 2021

ORGANIZER

Hrvatsko onkološko društvo - Hrvatski liječnički zbor
Croatian society of Oncology

Chair of the organizing committee

prof. dr. sc. Eduard Vrdoljak, dr. med.

Vice President:

Stjepko Pleština

Secretaries:

Antonio Juretić, Damir Gugić, Ingrid Belac Lovasić

Organizing committee:

Ante Bolanča
Lidija Beketić Orešković
Tanja Čufer
Višnja Matković
Miroslav Samaržija
Mladen Solarić
Stipislav Jadrijević
Nina Dabelić
Marijo Boban
Marko Zelić
Snježana Tomić
Ante Ćorušić
Martina Bašić Koretić
Josipa Flam

Scientific committee:

Tanja Badovinac-Črnjević
Goran Golčić
Davor Štimac
Herman Haller
Marko Jakopović
Tomislav Omrčen
Josip Paladino
Boris Ružić
Sven Seiwerth
Hrvoje Šobat
Dag Zahirović
Ariana Znaor
Inga Marjanović
Branka Petrić Miše
Marijana Jazvić
Jasna Radić

Sponsors and exhibitors:

ABBOTT
AMGEN
ASTELLAS
ASTRAZENECA
BAYER
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB
ELI LILLY
FARMEX
"JANSSEN: PHARMACEUTICAL COMPANIES
OF JOHNSON&JOHNSON"
KEMOMED

MERCK
MSD
NOVARTIS
OKTAL PHARMA
PFIZER
PFIZER HOSPITAL BU
PHARMASWISS
PLIVA
ROCHE
SANDOZ
SANOFI GENZYME
SERVIER
TAKEDA

Contents

ORAL PRESENTATIONS

GENERAL	3
Ivan Radoš	
S1 - Neuropathic pain - therapeutic approach	3
BREAST CANCER	5
Natalija Dedić Plavetić, Marija Križić	
S2 - The role of neoadjuvant therapy of breast cancer today	5
Marija Ban	
S3 - Optimal sequencing in luminal metastatic breast cancer treatment	7
Marija Balić	
S4 - Optimal treatment of metastatic HER2 positive breast cancer patients	9
Martina Bašić Koretić, Majana Soče, Maja Baučić, Sanja Šandrk, Tena Mlinarić Koprivanac, Ivan Zrilić, Dora Šimović	
S5 - Triple negative breast cancer treatment: current standards and future perspective	10
Marija Kraljević, Inga Marijanović	
S6 - Metastatic breast cancer as an initial diagnosis: a case report	12
Ana-Marija Bukovica Petrc, Eleonora Cini Tešar, Ingrid Belac-Lovasić	
S7 - Case report of metastatic breast cancer during pregnancy	13
Nikolina Lonjak, Ana Tečić Vuger	
S8 - Case report: patient with visceral crisis	14
LUNG CANCER	15
Miroslav Samaržija, Ante Marušić, Kristina Krpina, Ivana Kučić, David Stipan Žižić, Lidija Ljubičić, Latinka Bassara, Ante Zovko, Boris Brkljačić, Marko Jakopović	
S9 - Nationwide lung cancer screening program – Croatian model	15
Marko Jakopović, Ante Marušić, Goran Madžarac, Lela Bitar, Fran Seiwerth, Kristina Krpina, Miroslav Samaržija	
S10 - Novelties in adjuvant and neoadjuvant treatment of NSCLC	16

Marijo Boban	
S11 - The possibilities of non-small cell lung cancer treatment with targeted therapy in Croatia	18
Ivana Canjko, Luka Perić, Mirela Šambić Penc, Josipa Flam, Damir Gugić	
S12 - Toxicity of immunotherapy - individual approach	20
Milena Peitl	
S13 - Radiotherapy of NSCLC brain metastases in the age of targeted therapy and immunotherapy	21
Jasna Radić, Jasmina Marić Brozić, Kristina Urch, Ana Fröbe	
S14 - Why are we not successful in treatment of small cell lung cancer?	23
Maja Kolak, Ani Mihaljević Ferari, Ingrid Belac Lovasić	
S15 - Case report: treatment of alk-positive lung cancer	25
Tanja Čujić, Suzana Mladinov	
S16 - The reinitiation of immunotherapy after immunologically caused pneumonitis - a case report of lung cancer	27
GASTROINTESTINAL TUMORS	29
Josipa Flam, Mirela Šambić Penc, Ivana Canjko, Damir Gugić, Luka Perić, Ilijan Tomaš	
S17 - Perioperative treatment of gastric cancer and its implementation in Croatia	29
Robert Šeparović	
S18 - Metastatic colon cancer - is there room for personalized treatment?	30
Vesna Bišof	
S19 - Controversies in treatment of rectal cancer	32
Lidija Bošković	
S20 - The most recent advances in immunotherapy with checkpoint inhibitors in gastrointestinal cancers	34
Davor Kust, Jasmina Marić Brozić, Nina Dabelić, Ana Fröbe	
S21 - The role of targeted and radionuclide therapy in the contemporary treatment of neuroendocrine neoplasms	36
Neva Purgar Levarda, Marin Šunjić, Jasna Radić, Željko Soldić, Jasmina Marić Brozić, Davor Kust, Ana Fröbe	
S22 - Anal cancer – case presentation	38
Dora Tomek, Juraj Prejac	
S23 - Multimodal and multidisciplinary approach to patient with hepatocellular carcinoma: a case report	39

Križo Katinić, Maristela Šakić, Marijana Jazvić, Marijana Bogadi	
S24 - How to bear and endure illness?	40
Ana Fröbe, Pierfrancesco Franco	
S25 - Burnout among health care professionals in COVID19 pandemic	40
GYNECOLOGICAL TUMORS	43
Tihana Boraska Jelavić	
S26 - Place of immunotherapy in treatment of cervical cancer	43
Kristina Katić, Višnja Matković	
S27 - Optimal sequencing treatment of ovarian cancer	45
Jasna Marušić	
S28 - Personalized treatment of endometrial cancer	47
Dora Čerina, Ivana Tica Sedlar	
S29 - Diagnostic and treatment approach to the newly diagnosed metastatic uterine cancer in the era of precision oncology: a case report	49
Antonela Vrljičak, Blanka Jakšić, Ana Fröbe	
S30 - Granulosa cell tumor - case report	51
MELANOMA AND SARCOMA	52
Luka Simetić	
S31 - The current state of adjuvant therapies of melanoma - new standards - new hope for melanoma patients	52
Nina Dabelić, Jasmina Marić Brozić, Ana Fröbe	
S32 - The individualization of immunotherapy in melanoma patients	54
Dag Zahirović	
S33 - Role of radiotherapy in sarcoma treatment	57
Darko Kotromanović, Suzana Erić	
S34 - Case report: a patient with a mucosal melanoma	58
UROGENITAL TUMORS	61
Mladen Solarić	
S35 - Hypofractionated radiotherapy for prostate cancer - preconditions, benefits and limitations	61
Tomislav Omrčen	
S36 - Non-hormonal systemic treatment of prostate cancer	63

Igor Tomašković	
S37 - Comparison of surgical treatment and chemoradiotherapy for bladder preservation for localized muscle invasive bladder cancer - urologist view	64
Jure Murgić, Marijana Jazvić, Ana Fröbe	
S38 - Contemporary bladder-sparing management of muscle-invasive bladder cancer - oncologist standpoint	66
Ante Strikić	
S39 - Upcoming possibilities for systemic treatment of advanced bladder cancer	68
Marijana Jazvić, Marija Miletić, Jure Murgić, Ana Fröbe	
S40 - Optimal sequencing of systemic therapy in metastatic renal cell carcinoma	70
Luka Perić, Mirela Šambić Penc, Ivana Canjko, Josipa Flam	
S41 - Role of radiotherapy in the treatment of locally advanced penile cancer	72
Sanja Šandrk, Milena Gnjidić	
S42 - Testicular cancer – an unexpected course of the disease	74
HEAD AND NECK TUMORS	76
Zoran Rakušić	
S43 - News in the treatment of head and neck cancers	76
Ana Mišir Krpan	
S44 - Challenges of CNS tumor treatment in the Republic of Croatia	78
POSTER PRESENTATIONS	
Ana Car Peterko, Manuela Avirović, Petra Valković Zujić, Koraljka Rajković Molek, Ingrid Belac Lovasić, Franjo Lovasić	
P1 - ALND can be omitted in at least 72% of breast cancer patients following neoadjuvant systemic treatment	83
Petra Lepetić, Petra Linarić, Dejana Jezernik, Kristina Kanceljak, Ana Tečić Vuger, Mirjana Pavlović, Ljubica Vazdar, Robert Šeparović	
P2 - Assessment of alopecia in cancer patients treated with CDK 4/6 inhibitors and antihormonal therapy according to patient related outcomes at the University Hospital for Tumors	85
Helena Tomljenović, Jure Murgić, Marijana Matijaš, Marijana Jazvić, Jasmina Marić Brozić, Iva Kirac, Ilija Guteša, Željko Soldić, Ana Fröbe	
P3 - Body image scale: psychometric validation on a sample of Croatian breast cancer patients	86

Ana Majić, Marija Ban, Matea Buljubašić, Dora Čerina, Marija Pancirov, Darijo Hrepić, Eduard Vrdoljak P4 - Breast cancer immunophenotype as predictor of response to neoadjuvant therapy – single institution experience from University Hospital of Split from 2017 – 2020	87
Ana-Marija Bukovica Petrc, Ivona Mićović, Jasna Marušić, Iva Skočilić, Maja Kolak, Ivona Jerković, Damir Vučinić, Ingrid Belac-Lovasić P5 - Cancer treatment during the COVID19 pandemic at the Clinic for Radiotherapy and Oncology, Clinical Hospital Center Rijeka	88
Antonela Vrljićak, Kristina Urch, Jasna Radić, Jasmina Marić Brozić, Jure Murgić, Ana Fröbe P6 - Clinical outcomes of patients with metastatic non- small cell lung cancer treated with pembrolizumab alone or in combination with chemotherapy - a single center experience	89
Dora Čerina, Matea Buljubašić, Ana Majić, Marija Pancirov, Darijo Hrepić, Eduard Vrdoljak P7 - Comprehensive genomic profiling (CGP) as a cornerstone for precision medicine in metastatic uterine cancer - a single institution experience for 2020	90
Marin Šunjić, Jasna Radić, Željko Soldić, Jasmina Marić Brozić, Davor Kust, Jure Murgić, Ana Fröbe P8 - Concurrent chemoradiotherapy in patients with anal squamous cell carcinomas - a single center experience	92
Antonio Juretić P9 - Cutaneous melanoma neoadjuvant modern systemic therapy: a comment	93
Kristina Katić, Višnja Matković P10 - Efficacy and safety of bevacizumab therapy in patients with cervical cancer: an one institution experience	96
Lana Jajac Bručić, Filip Grubišić Čabo, Josipa Jović Zlatović, Ivan Krečak P11 - Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the General Hospital of Šibenik-Knin country	97
Đeni Smilović Radojčić, David Rajlić, Nevena Obajdin, Manda Švabić Kolacio, Slaven Jurković P12 - Enhancing quality and safety of advanced radiation therapy treatments in Croatia under the IAEA project CRO6019 - an overview	98
Neva Purgar Levarda, Davor Kust, Jasna Radić, Jasmina Marić Brozić, Željko Soldić, Ana Fröbe P13 - Experience with trifluridine tipiracil in treatment of metastatic colorectal cancer - do real world data follow the results of clinical trials?	99

Tomislav Pavlović, Sanja Trtica, Rosana Troškot Perić, Igor Borić P14 - Giant lipoma with intrapelvic and extrapelvic extension presenting as a sciatic hernia	100
Helena Tomljenović, Jure Murgić, Marijana Matijaš, Marijana Jazvić, Jasmina Marić Brozić, Iva Kirac, Ilija Guteša, Željko Soldić, Ana Fröbe P15 - Hospital anxiety and depression scale: psychometric validation on a sample of Croatian breast cancer patients	101
Diana Maržić, Miran Čoklo, Blažen Marijić, Katarina Radobuljac, Nina Čuš, Ita Hadžisejdić, Milan Radojčić, Tatjana Šepić, Manuela Avirović, Tamara Braut P16 - Immunohistochemical patterns IMP3, KI-67, p53 and cyclin D1 in laryngeal carcinogenesis	103
Krešimir Tomić, Dragana Miletić, Sanda Čale, Gordana Berić Jozić P17 - Impact of COVID-19 pandemic on number of outpatient oncology visits: a single center experience	104
Petra Radić, Jure Murgić, Helena Tomljenović, Marijana Jazvić, Jasmina Marić Brozić, Iva Kirac, Ilija Guteša, Željko Soldić, Ana Fröbe P18 - Impact of type of primary surgery on quality of life, anxiety, depression and body image in breast cancer patients receiving adjuvant treatment: a cross-sectional study	105
Ana Majić, Marija Ban, Matea Buljubašić, Dora Čerina, Marija Pancirov, Darijo Hrepić, Eduard Vrdoljak P19 - Improvements in surgical approach to newly diagnosed breast cancer patients by implementing multidisciplinary – single center experience from University Hospital of Split	106
Mirjana Pavlović, Petra Lepetić, Petra Linarić, Ljubica Vazdar, Ana Tečić Vuger, Robert Šeparović P20 - Influence of body composition on quality of life (QoL) of breast cancer patients treated with adjuvant chemotherapy	108
Blanka Jakšić, Jure Murgić, Mirjana Budanec, Ana Fröbe P21 - Local disease control in patients with locally advanced cervical cancer treated in oncology and nuclear medicine clinic, UHC Sestre milosrdnice	109
Ana Car Peterko, Dolores Brajan, Manuela Avirović, Petra Valković Zujčić, Eleonora Cini Tešar, Damir Juranić, Ingrid Belac Lovasić, Franjo Lovasić P22 - Multidisciplinary breast cancer management in Clinical Hospital Centre Rijeka; compliance with eusoma benchmark quality indicators	110
Jure Murgić, Marijana Jazvić, Marija Miletić, Monika Ulamec, Ana Fröbe P23 - Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a pilot feasibility biomarker analysis	111

Marijo Boban, Matea Buljubašić, Darijo Hrepić, Tihana Boraska Jelavić, Lidija Bošković, Eduard Vrdoljak P24 - Nivolumab and atezolizumab as second-line treatment for non-small cell lung cancer - experience of the Department of Oncology University Hospital of Split	113
Blažen Marijić, Filip Tudor, Tamara Braut, Emina Babarović, Diana Maržić, Manuela Avirović, Milodar Kujundžić, Marko Velepich, Ita Hadžisejdić P25 - Nuclear EGFR strong expression in laryngeal squamous cell carcinoma affects a more aggressive biological behaviour	114
Damir Vučinić, Leo Kovač, Margita Belušić-Gobić, Maja Grahovac, Blaženka Grahovac, Dag Zahirović, Ingrid Belac-Lovasić, Gordana Zamolo P26 - PD-L1 expression is regulated by microphthalmia transcription factor (MITF) in nodular melanoma	116
Juraj Prejac, Tomislav Omrčen, Jasna Radić, Eduard Vrdoljak, Ana Fröbe, Stjepko Pleština P27 - Possible predictive factors for the effectiveness of trifluridine/tipiracil in refractory metastatic colorectal cancer. A multicenter exploratory analysis	117
Dora Čerina, Matea Buljubašić, Ana Majić, Andrija Katić, Darijo Hrepić, Eduard Vrdoljak P28 - Precision oncology throughout the comprehensive genomic profiling (CGP) - a single institution cross-sectional data for the 2020	118
Snježana Ramić, Melita Perić Balja, Ana Tečić Vuger, Robert Šeparović P29 - Preliminary results of PIK3CA mutation analysis in advanced breast cancer	120
Marin Šunjić, Jasmina Marić Brozić, Nina Dabelić, Kristina Urch, Jure Murgić, Mirna Šitum, Ana Fröbe P30 - Prognostic relevance of lactate dehydrogenase in stage IV melanoma with known braf mutation status	121
Marin Prpić, Davor Kust, Jure Murgić, Neva Purgar Levarda, Petar Suton, Neno Živković, Ivan Kruljac, Ana Fröbe P31 - Radiotherapy induced hypothyroidism predicts progression-free survival in head and neck cancer patients	122
Marija Miletić, Marijana Jazvić, Jure Murgić, Ana Fröbe P32 - Real world experience in treatment of patients with advanced kidney cancer across therapy lines: single institution analysis from large tertiary center	123
Žana Saratlija Novaković, Toni Boban, Tihana Boraska Jelavić, Tomislav Omrčen, Marijan Šitum, Dubravka Ledina, Ante Strikić, Zdravka Rakuljić, Katarina Vilović, Davor Librenjak, Eduard Vrdoljak P33 - Results of treatment of muscle-invasive bladder cancer in University Hospital of Split: 2014.-2021	125
Rosana Troškot Perić, Dubravka Jandrić, Gabrijela Stanić, Ivo Soldo P34 - Retroperitoneal Castelman's disease	126

Nevena Obajdin, Đeni Smilović Radojčić, Manda Švabić Kolacio, David Rajlić, Ingrid Belac-Lovasić, Slaven Jurković	
P35 - Retrospective gamma analysis of patient absorbed dose distributions in a view of new tolerance criteria recommendations	127
Petra Linarić, Petra Lepetić, Dejana Jezernik, Kristina Kanceljak, Ana Tečić Vuger, Mirjana Pavlović, Ljubica Vazdar, Robert Šeparović	
P36 - TDM-1 for HER2-positive advanced breast cancer – clinical practice experience at University Hospital for Tumors	128
Barbara Čandrlić, Petra Valković Zujić, Ana Car Peterko, Manuela Avirović	
P37 - The accuracy of breast magnetic resonance imaging in predicting pathologic response to neoadjuvant chemotherapy	129
Marija Pancirov, Ana Majić, Dora Čerina, Snježana Tomić, Eduard Vrdoljak	
P38 - The first experience of PIK3CA testing in Clinical Hospital Center Split – what our results are?	131
Marija Ban, Lidija Bošković, Jelena Viculin, Matea Buljubašić, Eduard Vrdoljak	
P39 - The first insight in immunotherapy with checkpoint inhibitors for metastatic colorectal cancer in our daily practice	132
Ana Majić, Marija Ban, Matea Buljubašić, Dora Čerina, Marija Pancirov, Darijo Hrepić, Eduard Vrdoljak	
P40 - The impact of multidisciplinary in patterns of care in newly diagnosed breast cancer patients	133
Ana Majić, Marija Ban, Matea Buljubašić, Dora Čerina, Marija Pancirov, Darijo Hrepić, Eduard Vrdoljak	
P41 - The role of hormonal therapy as treatment option for neoadjuvant breast cancer – is less more?	134
Luka Novosel	
P42 - Thermal ablation in oligometastatic lung disease	136
Petra Valković Zujić, Ana Car Peterko, Damir Grebić, Manuela Avirović, Ivan Mikuličić	
P43 - Tomosynthesis guided vacuum-assisted breast biopsy is a safe alternative to diagnostic surgical biopsy in the setting of mammography-suspicious, ultrasound-occult breast lesions	137
Marija Miletić, Marijana Jazvić, Jure Murgić, Luka Ljubešić, Ana Fröbe	
P44 - Treatment outcomes and patterns of relapse following active surveillance for stage i testicular germ-cell cancer using MRI-based surveillance strategy: single center experience	138
Luka Novosel	
P45 - Vertebral augmentation as a treatment option in metastatic disease of the spine .	139
AUTHOR INDEX	141